Navigation Links
Johnson & Johnson honors 2008 recipients of the Dr. Paul Janssen Award for Biomedical Research
Date:9/10/2008

Beerse, Belgium September 10, 2008 The 2008 recipients of The Dr. Paul Janssen Award for Biomedical Research, Professor Marc Feldmann, FMedSci, FAA, FRS and Emeritus Professor Sir Ravinder Maini, FRCP, FMedSci, FRS of the Kennedy Institute of Rheumatology, Imperial College London, are being honored during a scientific symposium today and at a formal award ceremony at the Dr. Paul Janssen Research Center in Beerse, Belgium tomorrow. Feldmann and Maini received the $100,000 prize for their role in the discovery of tumor necrosis factor-alpha (TNF-alpha) as an effective therapeutic target for rheumatoid arthritis and other chronic inflammatory conditions.

"Thanks to their pioneering biomedical research, Feldmann and Maini have significantly improved the lives of millions of patients with chronic inflammatory conditions," said Paul Stoffels, company group chairman, Global Research and Development, Pharmaceuticals, Johnson & Johnson. "We are delighted that the 2008 Dr. Paul Janssen Award is going to two researchers with a lifelong commitment to translational research. Their achievements would have been greatly appreciated by Dr. Paul Janssen, who himself was instrumental in the development of many important medicines."

For more than 20 years, Feldmann and Maini have collaborated on basic research and clinical trials that have transformed the treatment of people diagnosed with chronic inflammatory conditions. Feldmann and Maini investigated the role of cytokines, protein messenger molecules that drive inflammation, and found that a single cytokine, TNF-alpha, was responsible for the debilitating symptoms of inflammatory disease. In seeking ways to block TNF-alpha, they studied a monoclonal antibody previously developed for an unrelated condition. Clinical trials revealed rapid and dramatic improvement of rheumatoid disease activity with anti-TNF therapy, ultimately influencing the development of several anti-TNF drugs that are used routine
'/>"/>

Contact: Lisa Vaga
lvaga@its.jnj.com
908-670-0363
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Source:Eurekalert

Page: 1 2

Related biology news :

1. Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT
2. M&Ms as diet food? 100-calorie pack misconceptions
3. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
4. Texas A&M researchers develop tool to study complex clusters of genes
5. Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate
6. Male seahorses are natures Mr. Mom, Texas A&M researchers say
7. Nobel laureate Dr. Linda Buck elected to American Academy of Arts & Sciences 2008 Class of Fellows
8. SAGE launches new journal -- ICAN: Infant, Child, & Adolescent Nutrition
9. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
10. AMNH scientists grace Science & Nature covers
11. Genetic Engineering & Biotechnology News reports on cancer biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... native flora is in sourcing genetically diverse seed not ... seed. "A common belief is that local native ... projects," says Dr Linda Broadhurst from CSIRO, Australia,s national ... that local seed is adapted to local conditions and ...
... A wild fungus has been found to produce a ... microscopic fungus, known as Gliocladium roseum (NRRL ... rainforest. Gary Strobel of Montana State University ... and that the particular diesel components produced can be ...
... discovered a metabolic deficiency in pancreatic cancer cells that ... deadliest of all cancers. Published in the October ... study results indicate that pancreatic cancer cells cannot produce ... in cell division, immune function and hormone regulation. By ...
Cached Biology News:Obscure fungus produces diesel fuel components 2UC Davis researchers discover Achilles' heel in pancreatic cancer 2UC Davis researchers discover Achilles' heel in pancreatic cancer 3
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
(Date:12/15/2014)... -- Origin Agritech Limited (NASDAQ GS: SEED) (" Origin ", or ... in China , today announced that the ... September 30, 2014, before the market opens on Thursday, January ... on January 8, 2015, at 8:00 a.m. ET / 9:00 ... results. To participate in the call, please dial +1-888-346-8982 in ...
(Date:12/13/2014)... Maryland (PRWEB) December 12, 2014 Clarassance, ... today announced its new name: Therabron Therapeutics , ... therapy and bronchioles (a type of structure in the ... the company’s mission to develop novel protein therapeutics for ... of directors decided to change the name to mark ...
(Date:12/13/2014)... 13, 2014 According to population studies: ... between now and 2030." If a population explosion like ... most populous state in the country. , To that ... the Future of North Carolina Forum on December 16th ... have the necessary infrastructure in place? Enough clean water? ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2
... , , STAMFORD, Conn. ... and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced ... Intermezzo ((R)) (zolpidem tartrate sublingual tablet) in the United States. If ... ((R)) has the potential to be the first prescription sleep aid ...
... ... Terrosa Technologies, a provider of Cloud and SaaS ... world wide sales, marketing and distribution responsibilities with Integrated Clinical ... collaboration Clinical Trial Management System (CTMS) tool for the pharmaceutical ...
... time bomb, a deadly mechanism that can be used against ... Universiteit Brussel (VUB) were able to determine the structure and ... for finding ways to set the clock on this internal ... new class of antibiotics. The research was accepted for ...
Cached Biology Technology:Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 2Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 3Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 4Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 5Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 6Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 7Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3Bacteria pack their own demise 2Bacteria pack their own demise 3
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Request Info...
Amyloid stain....
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Biology Products: